193 related articles for article (PubMed ID: 25482593)
1. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015 Jan; 15(1):129-41. PubMed ID: 25482593
[TBL] [Abstract][Full Text] [Related]
2. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Jun; 14(6):751-60. PubMed ID: 24666215
[TBL] [Abstract][Full Text] [Related]
3. Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Curr Med Res Opin; 2015 May; 31(5):975-86. PubMed ID: 25708852
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
5. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
6. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
Chu D; Lacouture ME; Weiner E; Wu S
Clin Genitourin Cancer; 2009 Jan; 7(1):11-9. PubMed ID: 19213662
[TBL] [Abstract][Full Text] [Related]
7. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2014 Dec; 92(3):194-207. PubMed ID: 25028151
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
McLellan B; Kerr H
Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
[TBL] [Abstract][Full Text] [Related]
9. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
Valle JW; Faivre S; Hubner RA; Grande E; Raymond E
Cancer Treat Rev; 2014 Dec; 40(10):1230-8. PubMed ID: 25283354
[TBL] [Abstract][Full Text] [Related]
10. Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Shimada YJ
Acta Oncol; 2013 May; 52(4):691-702. PubMed ID: 23282114
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
12. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
Rosenbaum SE; Wu S; Newman MA; West DP; Kuzel T; Lacouture ME
Support Care Cancer; 2008 Jun; 16(6):557-66. PubMed ID: 18274784
[TBL] [Abstract][Full Text] [Related]
13. Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.
Teo YL; Chong XJ; Chue XP; Chau NM; Tan MH; Kanesvaran R; Wee HL; Ho HK; Chan A
Cancer Chemother Pharmacol; 2014 Feb; 73(2):381-8. PubMed ID: 24306119
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
Richards CJ; Je Y; Schutz FA; Heng DY; Dallabrida SM; Moslehi JJ; Choueiri TK
J Clin Oncol; 2011 Sep; 29(25):3450-6. PubMed ID: 21810682
[TBL] [Abstract][Full Text] [Related]
15. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Lipworth AD; Robert C; Zhu AX
Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
[TBL] [Abstract][Full Text] [Related]
16. Blackberry-induced hand-foot skin reaction to sunitinib.
Boone SL; Jameson G; Von Hoff D; Lacouture ME
Invest New Drugs; 2009 Aug; 27(4):389-90. PubMed ID: 18998055
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
18. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Je Y; Schutz FA; Choueiri TK
Lancet Oncol; 2009 Oct; 10(10):967-74. PubMed ID: 19767240
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis.
Suwattee P; Chow S; Berg BC; Warshaw EM
Arch Dermatol; 2008 Jan; 144(1):123-5. PubMed ID: 18209189
[No Abstract] [Full Text] [Related]
20. The use of sunitinib in renal cell carcinoma: where are we now?
Czarnecka AM; Szczylik C; Rini B
Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]